These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23706986)

  • 1. NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.
    Pinilla-Dominguez P; Richardson J; Robertson J; Adam J
    Lancet Oncol; 2013 Jul; 14(8):691-2. PubMed ID: 23706986
    [No Abstract]   [Full Text] [Related]  

  • 2. NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer.
    Dyer M; Richardson J; Robertson J; Adam J
    Lancet Oncol; 2013 Jul; 14(8):689-90. PubMed ID: 23706983
    [No Abstract]   [Full Text] [Related]  

  • 3. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
    Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
    Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
    Eisenhauer EL; Zanagnolo V; Cohn DE; Salani R; O'Malley DM; Sutton G; Callahan MJ; Cobb B; Fowler JM; Copeland LJ
    Gynecol Oncol; 2014 Aug; 134(2):262-6. PubMed ID: 24910452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.
    Dohrmann T; Kutup A; Mahner S; Müller V; Jaenicke F; Izbicki JR; Vashist YK
    J Clin Oncol; 2013 Apr; 31(12):e208-10. PubMed ID: 23509305
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of platinum-sensitive recurrent ovarian cancer.
    Pfisterer J; Ledermann JA
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S12-6. PubMed ID: 16716798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
    Li Y; Yang Y; Shang YM; Zheng H
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e92-4. PubMed ID: 25818742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Havrilesky LJ; Secord AA; Kulasingam S; Myers E
    Gynecol Oncol; 2007 Nov; 107(2):211-8. PubMed ID: 17870150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
    Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
    J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer.
    Wu MD; Wang Y; Ding T; Zhou YF; Song J; Liu XH; Wei MH; Yang QH; Zhou J; Wang SH; Lv QY
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e103-5. PubMed ID: 25818733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
    Kose MF; Meydanli MM; Tulunay G
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):437-43. PubMed ID: 16503860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
    Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
    Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer.
    Pfisterer J; Vergote I; Du Bois A; Eisenhauer E; ; ;
    Int J Gynecol Cancer; 2005; 15 Suppl 1():36-41. PubMed ID: 15839957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
    Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
    Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
    Aghajanian C; Goff B; Nycum LR; Wang Y; Husain A; Blank S
    Gynecol Oncol; 2014 Apr; 133(1):105-10. PubMed ID: 24508841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
    Giuliani J; Bonetti A
    Int J Gynecol Cancer; 2017 Nov; 27(9):1872-1876. PubMed ID: 28976446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
    Pfisterer J; Plante M; Vergote I; du Bois A; Hirte H; Lacave AJ; Wagner U; Stähle A; Stuart G; Kimmig R; Olbricht S; Le T; Emerich J; Kuhn W; Bentley J; Jackisch C; Lück HJ; Rochon J; Zimmermann AH; Eisenhauer E; ; ;
    J Clin Oncol; 2006 Oct; 24(29):4699-707. PubMed ID: 16966687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
    Richardson DL; Backes FJ; Seamon LG; Zanagnolo V; O'Malley DM; Cohn DE; Fowler JM; Copeland LJ
    Gynecol Oncol; 2008 Dec; 111(3):461-6. PubMed ID: 18829088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing gemcitabine regimens in ovarian cancer.
    Pecorelli S; Pasinetti B; Tisi G; Odicino F
    Semin Oncol; 2006 Apr; 33(2 Suppl 6):S17-25. PubMed ID: 16716799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.